Swiss Biotech Report 2006

33PRIVATE SWISS BIOTECH COMPANIESPUBLIC SWISS BIOTECH COMPANIESRevenues, R&D expenses, profits/losses >>CHF/mio1800160014001200100080060040020001678 15491596357 350 34525 22 22Revenues R&D expenses Profits/ losses200520042003CHF/mio450040003500300025002000150010005000428339243438RevenuesR&D expenses-165657 5012005200420031176 1036 827Profits/lossesSource: Ernst &YoungSource: Annual reports and website informationNumber of employees, liquidity >>CHF/mio80007000600050004000300020001000066836063 5926Employees492 462 426Liquidity200520042003CHF/mio9000800070006000500040003000200010000771374626920Employees13951134Liquidity1897200520042003Source: Ernst &YoungPlease note:• All figures are headquarter counted• As some private companies do not disclose financialfigures, the above figures represent Ernst & Young’s bestestimateSource: Annual reports and website informationPlease note:• All figures are headquarter counted• The 2005 data in these tables are based on the informationavailable in early March 2006, when this report wascompiled. At this time, some of the companies had notyet disclosed the final financial figures for 2005. Therefore,some figures were carefully extrapolated on the basis ofnewest interim data publicly available (e.g. Q3 2005).• Presented public profit/loss data includes Serono fine inthe amount of CHF 903 million.